Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?

Minerva Urol Nephrol. 2022 Feb;74(1):1-4. doi: 10.23736/S2724-6051.21.04613-9. Epub 2021 Aug 2.

Authors

Marco Paciotti^{1

2}, Roberto Contieri^{1

2}, Vittorio Fasulo^{3

2}, Paolo Casale², Alberto Saita², Nicolò M Buffi^{1

2}, Giovanni Lughezzani^{1

2}, Pietro Diana^{1

2}, Nicola Frego^{1

2}, Giorgio Guazzoni^{1

2}, Massimo Lazzeri², Rodolfo Hurle²

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy.
² Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
³ Department of Biomedical Sciences, Humanitas University, Milan, Italy - vittorio.fasulo@humanitas.it.

PMID: 34338493
DOI: 10.23736/S2724-6051.21.04613-9

No abstract available

MeSH terms

COVID-19*
Humans
Pandemics
Recurrence
SARS-CoV-2
Urinary Bladder Neoplasms* / diagnosis
Urinary Bladder Neoplasms* / epidemiology
Urinary Bladder Neoplasms* / pathology
Watchful Waiting*